Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Knopp Biosciences Completes Enrollment In Phase 2 Trial Of Oral Dexpramipexole In Eosinophilic Asthma is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with ... Read More
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
"Enrollment of the final patient in Part 1 our Phase 2a clinical trial of DA-1241 ... both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides ... Read More
Celldex completes patient enrollment for Phase 2 urticaria trial
HAMPTON, N.J. - Celldex (NASDAQ:CLDX) Therapeutics, Inc. (NASDAQ:CLDX) has announced the completion of patient enrollment for its Phase 2 clinical trial ... is based on a press release statement ... Read More
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
The ROSELLA trial has the same design as Corcept's positive Phase 2 study, in which patients ... Statements in this press release, other than statements of historical fact, are forward-looking ... Read More
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with ... Read More
Celldex completes patient enrollment for Phase 2 urticaria trial
HAMPTON, N.J. - Celldex (NASDAQ:CLDX) Therapeutics, Inc. (NASDAQ:CLDX) has announced the completion of patient enrollment for its Phase 2 clinical trial of barzolvolimab ... for this article is based ... Read More
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
The ROSELLA trial has the same design as Corcept's positive Phase 2 study, in which patients who received relacorilant ... Forward-Looking Statements Statements in this press release, other than ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus